Table 6.
Results of Autologous Hematopoietic Stem Cell Transplant in Pediatric Relapsed/Refractory Anaplastic Large Cell Lymphoma
| Author (Reference) | N. Patients | Age (Years) | Years | Disease Status Before HSCT | Outcome (Years) |
|---|---|---|---|---|---|
| Brugieres (2000)92 | 15 auto | < 18 | 1975–1997 | CR | DFS 45% (3) |
| Mori (2006)93 | Auto 8, allo 6 | < 18 | 1989–2003 | CR | RFS 33% auto; 100% allo (3) |
| Won (2006)70 | 7 auto | < 18 | 1997–2004 | CR, no CR | EFS 100% (2) |
| Gross (2010)78 | Auto 24, allo 12 | < 18 | 1990–2005 | NR | EFS 35% auto; 46% allo (5) |
| Woessmann (2011)95 | 39 auto | < 18 | 1990–2003 | CR | EFS 59%; OS 77% (5) |
| Fukano (2015)94 | Auto 23, allo 24 | < 18 | 1990–2010 | CR 16/23 auto, CR 8/24 allo | EFS 38% auto; 50% allo (5) |
| Knorr (2020)96 | Auto 22, allo 36 | < 21 | 2004–2014 | CR 21/22 auto, NR allo | EFS 41% auto; 81% allo (5) |
Abbreviations: Allo, allogeneic transplant; auto, autologous transplant; EFS, event free survival; CR, complete remission; DFS, disease free survival; HSCT, hematopoietic stem cell transplant; NR, not reported; OS, overall survival; RFS, relapse free survival.